Secukinumab gets EC approval for treating hidradenitis suppurativa

Time : 2nd of June 2023 04:49:25 PM

Cosentyx® (secukinumab) became the only new biologic approved in the last decade for this condition. It provided rapid symptom relief by week 4, with increasing response rates for up to a year. The safety profile of the drug was already established across other indications. The drug is also used fot treating plaque psoriasis, spondylitis, spondyloarthritis, and arthritis.



secukinumab, hidradenitis suppurativa, EC

Recent Posts

An AI-assisted colonoscopy gets FDA approval
3rd of August 2023 02:43:05 PM

Severe sleep apnea tied to brain abnormalities
1st of August 2023 12:22:47 PM

FDA approves another OTC naloxone nasal spray
1st of August 2023 11:46:02 AM